APA (7th ed.) Citation

M, D. L., R, C., M, M., M, M., R, M., Z, B., . . . C, Z. (2022). Safety and Efficacy of Ribociclib in Combination with Letrozole in Patients with HR+, HER2- Advanced Breast Cancer: Results from the Italian Subpopulation of Phase 3b CompLEEment-1 Study. Targeted oncology, 17(6), 615. https://doi.org/10.1007/s11523-022-00913-x

Chicago Style (17th ed.) Citation

M, De Laurentiis, et al. "Safety and Efficacy of Ribociclib in Combination with Letrozole in Patients with HR+, HER2- Advanced Breast Cancer: Results from the Italian Subpopulation of Phase 3b CompLEEment-1 Study." Targeted Oncology 17, no. 6 (2022): 615. https://doi.org/10.1007/s11523-022-00913-x.

MLA (9th ed.) Citation

M, De Laurentiis, et al. "Safety and Efficacy of Ribociclib in Combination with Letrozole in Patients with HR+, HER2- Advanced Breast Cancer: Results from the Italian Subpopulation of Phase 3b CompLEEment-1 Study." Targeted Oncology, vol. 17, no. 6, 2022, p. 615, https://doi.org/10.1007/s11523-022-00913-x.